NUCANA PLC-ADR (NCNA)
US67022C2052 - ADR
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions...
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States...
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy. Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Resp
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses,...
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303...
NCNA Stock Earnings: NuCana Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ:NCNA) just reported results for the second quarter of 2024.NuCan...
NCNA Stock Earnings: NuCana Beats EPS for Q2 2024
NCNA stock results show that NuCana beat analyst estimates for earnings per share the second quarter of 2024.
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
NuCana to Present at the Jefferies Global Healthcare Conference
NuCana to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief...
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and...
NCNA Stock Earnings: NuCana Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NuCana (NASDAQ:NCNA) just reported results for the first quarter of 2024.NuCana...
NCNA Stock Earnings: NuCana Beats EPS for Q1 2024
NCNA stock results show that NuCana beat analyst estimates for earnings per share the first quarter of 2024.
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled ...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a...
NuCana Announces Completion of ADS Ratio Change
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the...